Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lukasz F Grochola

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cold Spring Harbor Perspectives in Biology|May 11, 2010
Single-nucleotide polymorphisms in the p53 signaling pathwayLukasz F Grochola, Jorge Zeron-Medina, Sophie Mériaux, et al.
International Journal of Cancer|June 25, 2009
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survivalThomas Greither, Lukasz F Grochola, Andrej Udelnow, et al.
Pancreas|September 16, 2009
MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formationLukasz F Grochola, Thomas H Müller, Gareth L Bond, et al.
International Journal of Cancer|July 30, 2010
A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrenceAlexei Vazquez, Diptee Kulkarni, Lukasz F Grochola, et al.
Cancer Research|December 10, 2009
Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survivalAlexei Vazquez, Lukasz F Grochola, Elisabeth E Bond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survivalLukasz F Grochola, Alexei Vazquez, Elisabeth E Bond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2016
CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal AdenocarcinomaGiovanni Stracquadanio, Bart Vrugt, Renata Flury, et al.
Cancer Research|June 16, 2012
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancerKristiaan Lenos, Anna M Grawenda, Kirsten Lodder, et al.
The British Journal of Surgery|April 25, 2024
Liver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohortRemon Korenblik, Jan Heil, Jens Smits, et al.
Cancer Research|February 9, 2021
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug ResponsePing Zhang, Isaac Kitchen-Smith, Lingyun Xiong, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cold Spring Harbor Perspectives in Biology|May 11, 2010
Single-nucleotide polymorphisms in the p53 signaling pathwayLukasz F Grochola, Jorge Zeron-Medina, Sophie Mériaux, et al.
International Journal of Cancer|June 25, 2009
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survivalThomas Greither, Lukasz F Grochola, Andrej Udelnow, et al.
Pancreas|September 16, 2009
MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formationLukasz F Grochola, Thomas H Müller, Gareth L Bond, et al.
International Journal of Cancer|July 30, 2010
A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrenceAlexei Vazquez, Diptee Kulkarni, Lukasz F Grochola, et al.
Cancer Research|December 10, 2009
Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survivalAlexei Vazquez, Lukasz F Grochola, Elisabeth E Bond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survivalLukasz F Grochola, Alexei Vazquez, Elisabeth E Bond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2016
CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal AdenocarcinomaGiovanni Stracquadanio, Bart Vrugt, Renata Flury, et al.
Cancer Research|June 16, 2012
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancerKristiaan Lenos, Anna M Grawenda, Kirsten Lodder, et al.
The British Journal of Surgery|April 25, 2024
Liver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohortRemon Korenblik, Jan Heil, Jens Smits, et al.
Cancer Research|February 9, 2021
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug ResponsePing Zhang, Isaac Kitchen-Smith, Lingyun Xiong, et al.
Pageof 1